Business Context and Reporting Period
Company: MESA LABORATORIES INC
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2010
Business Overview: Mesa Laboratories designs, manufactures, and markets instruments and disposable products for industrial and healthcare applications. Key product lines include DATATRACE data loggers, RAVEN and SGM BIOTECH biological indicators, Dialysate Meters for kidney dialysis, TORQO torque testing systems, and NUSONICS fluid measurement systems.
Key Financial Metrics (Fiscal Year 2010)
| Metric | 2010 Value | 2009 Value |
|---|---|---|
| Net Sales | $21,929,000 | $21,536,000 |
| Gross Profit | $13,194,000 | $13,817,000 |
| Gross Margin | 60% | 64% |
| Operating Income | $7,368,000 | $7,608,000 |
| Net Income | $4,769,000 | $4,790,000 |
| Diluted EPS | $1.45 | $1.48 |
| Cash and Investments | $10,471,000 | $9,111,000 |
| Working Capital | $18,530,000 | $17,109,000 |
| Current Ratio | 11:1 | 13:1 |
| Total Debt | $0 (at year-end) | $0 |
Note: Debt figures reflect the balance sheet as of March 31, 2010. Significant debt was incurred in April 2010 to finance acquisitions (see below).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% ($393,000) compared to fiscal 2009. Growth was driven by a 7% increase in Raven Biological Indicators and a 2% increase in Medical products, partially offset by a 19% decline in NUSONICS sales and a 7% decline in DATATRACE sales.
- Margin Compression: Gross margin decreased from 64% to 60%. This was attributed to a shift in product mix toward lower-margin Raven products, lower DATATRACE sales volume, and the initial manufacturing costs associated with the newly acquired TORQO product line.
- Profitability: Net income decreased slightly by 0.4% ($21,000). This was primarily due to increased cost of sales and decreased interest income, partially offset by reduced selling and marketing expenses and lower state income taxes.
- Acquisitions:
- TORQO: Acquired in late 2009; contributed $330,000 in sales in 2010.
- SGM BIOTECH: Acquired April 27, 2010 (post-year-end) for $11.7 million cash. Facility acquired April 30, 2010 for $2.15 million.
Guidance, Outlook, and Risks
- Financing for Acquisitions: To fund the SGM BIOTECH acquisition, the company entered a $7 million credit facility in April 2010. This includes a $3 million reducing line (fully utilized) and a $4 million revolving line ($1.52 million utilized). Interest rates are variable with a 3.25% floor.
- Future Expenses: Management expects a significant rise in amortization expense in fiscal 2011 due to the TORQO and SGM BIOTECH acquisitions.
- Operational Outlook: The company plans to consolidate TORQO manufacturing into its Lakewood, CO facility by December 2010 to reduce costs. Strong order rates for TORQO products were noted in Q4 2010.
- Risk Factors:
- Intense competition from larger companies with greater resources.
- Dependence on a single customer representing ~14% of revenue.
- Regulatory risks associated with FDA compliance for medical devices.
- Variable interest rate exposure on new debt facilities.
Investor Verification Checklist
- Debt Servicing: Verify the impact of the new $7 million credit facility on future interest expenses and cash flow, given the variable rate structure.
- Amortization Impact: Monitor Q1 2011 earnings for the anticipated increase in amortization expenses from the SGM BIOTECH and TORQO acquisitions.
- Customer Concentration: Assess the stability of the single customer representing 14% of total revenue.
- Margin Recovery: Track whether the consolidation of TORQO manufacturing achieves the projected cost reductions and margin improvements.
- Integration Success: Evaluate the revenue contribution and integration progress of the SGM BIOTECH acquisition in the first full quarter of ownership.